drugset
drugset / Trial / NCT05526807

Ursodeoxycholic Acid in C. Difficile Infection

NCT05526807 ↗

Terminated 6 enrolled Nottingham University Hospitals NHS Trust
NaSingle-groupOpen-labelPrevention

Summary

The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid

Timeline

Start
2019-05-08
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule — Oral

Indications

Clostridium difficile colitis